MK PHARMA LIMITED

Company Registration Number:
08737318 (England and Wales)

Unaudited abridged accounts for the year ended 31 December 2024

Period of accounts

Start date: 01 January 2024

End date: 31 December 2024

MK PHARMA LIMITED

Contents of the Financial Statements

for the Period Ended 31 December 2024

Balance sheet
Notes

MK PHARMA LIMITED

Balance sheet

As at 31 December 2024


Notes
2024
2023


£
£
Fixed assets
Intangible assets: 3 1,750,000 1,750,000
Tangible assets: 4 349,951 356,777
Total fixed assets: 2,099,951 2,106,777
Current assets
Stocks: 31,798 29,132
Debtors:   272,711 230,442
Cash at bank and in hand: 98,726 159,076
Total current assets: 403,235 418,650
Creditors: amounts falling due within one year:   (744,700) (732,076)
Net current assets (liabilities): (341,465) (313,426)
Total assets less current liabilities: 1,758,486 1,793,351
Creditors: amounts falling due after more than one year:   (878,007) (948,456)
Total net assets (liabilities): 880,479 844,895
Capital and reserves
Called up share capital: 100 100
Revaluation reserve:5525,000525,000
Other reserves: 35,000 35,000
Profit and loss account: 320,379 284,795
Shareholders funds: 880,479 844,895

The notes form part of these financial statements

MK PHARMA LIMITED

Balance sheet statements

For the year ending 31 December 2024 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with Section 444(2A).

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The directors have chosen to not file a copy of the company’s profit & loss account.

This report was approved by the board of directors on 29 September 2025
and signed on behalf of the board by:

Name: Idris Karimjee
Status: Director

The notes form part of these financial statements

MK PHARMA LIMITED

Notes to the Financial Statements

for the Period Ended 31 December 2024

1. Accounting policies

These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

MK PHARMA LIMITED

Notes to the Financial Statements

for the Period Ended 31 December 2024

2. Employees

2024 2023
Average number of employees during the period 13 12

MK PHARMA LIMITED

Notes to the Financial Statements

for the Period Ended 31 December 2024

3. Intangible Assets

Total
Cost £
At 01 January 2024 1,900,000
At 31 December 2024 1,900,000
Amortisation
At 01 January 2024 150,000
At 31 December 2024 150,000
Net book value
At 31 December 2024 1,750,000
At 31 December 2023 1,750,000

MK PHARMA LIMITED

Notes to the Financial Statements

for the Period Ended 31 December 2024

4. Tangible Assets

Total
Cost £
At 01 January 2024 465,187
Additions 3,500
Disposals (11,634)
At 31 December 2024 457,053
Depreciation
At 01 January 2024 108,410
Charge for year 8,433
On disposals (9,741)
At 31 December 2024 107,102
Net book value
At 31 December 2024 349,951
At 31 December 2023 356,777

MK PHARMA LIMITED

Notes to the Financial Statements

for the Period Ended 31 December 2024

5. Revaluation reserve

2024
£
Balance at 01 January 2024 525,000
Surplus or deficit after revaluation 0
Balance at 31 December 2024 525,000